Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
about
Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overviewTreatment of diffuse large B cell lymphomaEvolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateA rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort StudyRituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.Diagnosis and treatment of CD20 negative B cell lymphomas.Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma.Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone.Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860
Q26769596-FEFACC03-9884-4A20-821B-FAD3337919DEQ27006062-A0460F08-AF55-473A-9A76-7D5281F3BD58Q28078869-7BB76499-ABFC-46D5-BDFD-5F284ECAE7FCQ37119773-66B9CFBE-0E40-4237-9994-749CE01077B5Q37146688-139C05F9-52DB-40ED-9B0F-11BBCDCA00EAQ37520194-FE8649D6-D9CB-4017-8B87-A01F9AB08995Q37624237-772C8F66-2D63-4C9C-91B7-B49119627219Q37695075-64F01D5A-B76B-4F08-9A27-97ACDF7BCA61Q38674040-43A72A25-C90D-460A-AD2F-6174D3306984Q39132786-AD54D16A-7219-4F27-9914-0C5E3CEB169EQ40348207-0473C482-61D6-47AF-B4FF-1440687BDAEAQ47551132-7F147D62-3F00-4DB5-8F6B-D3E6B179F9FCQ48614611-A20E71E2-8F42-464B-9F0B-2379284EAE83Q50319166-CF755922-0C3B-4B99-A949-7D4BFC6DCC62Q58767936-687BCF39-47F1-4856-AE2D-0B756D7C0B30
P2860
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Long-term follow-up of dose-ad ...... by the Spanish PETHEMA Group.
@en
Long-term follow-up of dose-adjusted EPOCH plus rituximab
@nl
type
label
Long-term follow-up of dose-ad ...... by the Spanish PETHEMA Group.
@en
Long-term follow-up of dose-adjusted EPOCH plus rituximab
@nl
prefLabel
Long-term follow-up of dose-ad ...... by the Spanish PETHEMA Group.
@en
Long-term follow-up of dose-adjusted EPOCH plus rituximab
@nl
P2093
P2860
P50
P356
P1476
Long-term follow-up of dose-ad ...... d by the Spanish PETHEMA Group
@en
P2093
Ana Batlle
Andrés Lopez
Fernando Carnicero
Jose A García-Marco
Juan Bergua
Julio Prieto
Laura Gallur
Lucía Ferrando-Lamana
Luis A Lopez
Noelia Purroy
P2860
P304
P356
10.1111/BJH.13273
P407
P577
2014-12-18T00:00:00Z